Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.

New agents will change the therapeutic perspectives in advanced HCC and lead to a higher rate of objective responses, with possibilities of associating systemic therapy and surgery. Thus, the management of HCC will require more and more of an integrated, multidisciplinary and personalized approach.